'Stress protein' speeds progression of Alzheimer's
- Zero-tolerance towards communal violence, must act: Centre to states
- Varanasi: Violence breaks out during protest march, vehicles set ablaze
- Germany our natural partner, says Modi after meeting Merkel; 18 MoUs inked to boost trade
- Why the BJP finds itself in a spot before Gujarat local body polls
- Supreme Court suspends beef ban in Jammu & Kashmir for two months
A stress-related protein genetically linked to depression, anxiety and other psychiatric disorders contributes to the acceleration of Alzheimer's disease, a new study has found.
Researchers led by the University of South Florida found when the stress-related protein FKBP51 partners with another protein known as Hsp90 it prevents the clearance from the brain of the toxic tau protein associated with Alzheimer's disease.
Under normal circumstances, tau helps make up the skeleton of our brain cells.
The study was done using test tube experiments, mice genetically engineered to produce abnormal tau protein like that accumulated in the brains of people with Alzheimer's disease, and post-mortem human Alzheimer's brain tissue.
The researchers reported that FKBP51 levels increase with age in the brain, and then the stress-related protein partners with Hsp90 to make tau more deadly to the brain cells involved in memory formation.
Hsp90 is a chaperone protein, which supervises the activity of tau inside nerve cells. Chaperone proteins typically help ensure that tau proteins are properly folded to maintain the healthy structure of nerve cells.
However, as FKBP51 levels rise with age, they usurp Hsp90's beneficial effect to promote tau toxicity.
"We found that FKB51 commandeers Hsp90 to create an environment that prevents the removal of tau and makes it more toxic," said the study's principal investigator Chad Dickey, associate professor of molecular medicine at the USF Health Byrd Alzheimer's Institute.
"Basically, it uses Hsp90 to produce and preserve the bad tau," Dickey said.
The researchers concluded that developing drugs or other ways to reduce FKB51 or block its interaction with Hsp90 may be highly effective in treating the tau pathology featured in Alzheimer's disease, Parkinson's disease dementia and several other disorders associated with memory loss.
A previous study by Dickey and colleagues found that a lack of FKBP51 in old mice improved resilience to depressive behaviour.